New graft promises better healing after skin cancer removal
NCT ID NCT06919809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a special skin graft called X A-DERM™ mADM in 16 people who had Mohs surgery to remove skin cancers like basal cell carcinoma or squamous cell carcinoma. The graft has a micro-textured surface designed to help the wound heal faster and leave a better scar. Researchers checked healing with photos and scar assessments over 60 days. The goal was to see if this graft improves recovery compared to standard methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- X A-DERM™ microsurfaced acellular dermal matrix (mADM) graft
- What this could lead to
- If it works, this could provide a better way to heal wounds and reduce scarring after skin cancer removal surgery.
- What could go wrong
- This is a very small, single-arm study with only 16 participants, so results may not apply to everyone. The device is new and may not improve healing over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCC - BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bare Dermatology
Rockwall, Texas, 75032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a glowing drug light up head and neck tumors?
- Needle-Free light therapy shows promise for common skin cancer
- New imaging tool may help detect Eye-Area skin cancer without a biopsy
- Smartphone screening could catch skin cancer sooner
- Blue dye gel shows promise for treating inoperable skin cancer
- Blood test may predict cancer recurrence in head and neck patients